Paul Zemaitis1, Kiang Liu2, David R Jacobs3, Mary Cushman4, Ramon Durazo-Arvizu1, David Shoham1, Walter Palmas5, Richard Cooper1, Holly Kramer6. 1. Department of Public Health Sciences and. 2. Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois; 3. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota; Department of Nutrition, University of Oslo, Oslo, Norway; 4. Department of Pathology, University of Vermont, Colchester, Vermont; and. 5. Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York. 6. Department of Public Health Sciences and Department of Medicine, Division of Nephrology and Hypertension, Loyola University Health Sciences Center, Maywood, Illinois; hkramer@luc.edu.
Abstract
BACKGROUND AND OBJECTIVES: Cumulative exposure to elevated systolic BP (cumSBP) may affect progression of urine albumin excretion in the absence of diabetes. The objective of this study was to examine the association between cumSBP exposure and progression of spot urine albumin-to-creatinine ratio (UACR) in a multi-ethnic cohort of adults without diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The analysis included 3789 participants without severely increased urine albumin excretion or diabetes in the Multi-Ethnic Study of Atherosclerosis, a cohort of 6814 adults aged 45-84 years. UACR was measured at baseline and approximately 1.6, 3.1, and 9.4 years after the baseline examination. cumSBP was calculated as the summed average systolic BP (SBP; mmHg) between two consecutive examinations multiplied by the time between the two examinations (mmHg × year) and categorized as ≤ 1128 (SBP<120 mmHg), 1129-1222 (SBP ≥ 120-129 mmHg), 1223-1316 (SBP ≥ 130-130 mmHg), and > 1316 (SBP ≥ 140 mmHg). Baseline UACR was categori zed as normal, mildly increased, or moderately increased, and definite progression of UACR was defined as a persistently higher UACR category at subsequent examinations. No UACR progression was defined as remaining in the same UACR category across all examinations or regressing. RESULTS: In fully adjusted models, compared with cumSBP ≤ 1128 mmHg, cumSBP 1223-1316 and >1316 mmHg was associated with a 85% and 130% significantly higher odds of definite UACR progression (95% confidence interval, 24% to 178% and 56% to 243%, respectively) versus no UACR progression. Every 100-mmHg higher level of cumSBP was associated with a 1.23-fold higher odds of definite UACR progression (95% confidence interval, 1.13 to 1.34) versus no UACR progression. CONCLUSION: Exposure to higher cumSBP was associated with increased UACR progression among adults without diabetes.
BACKGROUND AND OBJECTIVES: Cumulative exposure to elevated systolic BP (cumSBP) may affect progression of urine albumin excretion in the absence of diabetes. The objective of this study was to examine the association between cumSBP exposure and progression of spot urine albumin-to-creatinine ratio (UACR) in a multi-ethnic cohort of adults without diabetes. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The analysis included 3789 participants without severely increased urine albumin excretion or diabetes in the Multi-Ethnic Study of Atherosclerosis, a cohort of 6814 adults aged 45-84 years. UACR was measured at baseline and approximately 1.6, 3.1, and 9.4 years after the baseline examination. cumSBP was calculated as the summed average systolic BP (SBP; mmHg) between two consecutive examinations multiplied by the time between the two examinations (mmHg × year) and categorized as ≤ 1128 (SBP<120 mmHg), 1129-1222 (SBP ≥ 120-129 mmHg), 1223-1316 (SBP ≥ 130-130 mmHg), and > 1316 (SBP ≥ 140 mmHg). Baseline UACR was categori zed as normal, mildly increased, or moderately increased, and definite progression of UACR was defined as a persistently higher UACR category at subsequent examinations. No UACR progression was defined as remaining in the same UACR category across all examinations or regressing. RESULTS: In fully adjusted models, compared with cumSBP ≤ 1128 mmHg, cumSBP 1223-1316 and >1316 mmHg was associated with a 85% and 130% significantly higher odds of definite UACR progression (95% confidence interval, 24% to 178% and 56% to 243%, respectively) versus no UACR progression. Every 100-mmHg higher level of cumSBP was associated with a 1.23-fold higher odds of definite UACR progression (95% confidence interval, 1.13 to 1.34) versus no UACR progression. CONCLUSION: Exposure to higher cumSBP was associated with increased UACR progression among adults without diabetes.
Authors: Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz Journal: JAMA Date: 2014-02-05 Impact factor: 56.272
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: M A Martínez; A Moreno; A Aguirre de Cárcer; R Cabrera; R Rocha; A Torre; A Nevado; T Ramos; J Neri; G Antón; I Miranda; P Fernández; E Rodríguez; A Miquel; J L Martínez; M Rodríguez; C Eisman; J G Puig Journal: J Hypertens Date: 2001-02 Impact factor: 4.844
Authors: David R Jacobs; Maureen A Murtaugh; Michael Steffes; Xinhua Yu; Jeffrey Roseman; Frederick C Goetz Journal: Am J Epidemiol Date: 2002-06-15 Impact factor: 4.897
Authors: Kristian Wachtell; Michael H Olsen; Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Markku S Nieminen; Peter M Okin; Vasilios Papademetriou; Carl E Mogensen; Knut Borch-Johnsen; Hans Ibsen Journal: J Hypertens Date: 2002-03 Impact factor: 4.844
Authors: Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy Journal: Am J Epidemiol Date: 2002-11-01 Impact factor: 4.897
Authors: Holly Kramer; Laura Colangelo; Cora E Lewis; David R Jacobs; Mark Pletcher; Kirstin Bibbins-Domingo; Alex Chang; David Siscovick; Michael Shlipak; Carmen A Peralta; Nisha Bansal; Paul Muntner; Kiang Liu Journal: Am J Hypertens Date: 2017-05-01 Impact factor: 2.689
Authors: Mahmoud Al Rifai; Andrew P DeFilippis; John W McEvoy; Michael E Hall; Ana Navas Acien; Miranda R Jones; Rachel Keith; Hoda S Magid; Carlos J Rodriguez; Graham R Barr; Emelia J Benjamin; Rose Marie Robertson; Aruni Bhatnagar; Michael J Blaha Journal: Atherosclerosis Date: 2017-01-19 Impact factor: 5.162
Authors: Michael J Sorich; Andrew Rowland; Ganessan Kichenadasse; Richard J Woodman; Arduino A Mangoni Journal: Br J Cancer Date: 2016-05-26 Impact factor: 7.640